Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 105Carcinoma, Hepatocellular 34Gastrointestinal Stromal Tumors 17Colonic Neoplasms 14Rectal Neoplasms 12Neoplasm Metastasis 12Liver Neoplasms 8Stomach Neoplasms 5Cholangiocarcinoma 5Pancreatic Neoplasms 4Esophageal Neoplasms 4Sarcoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Colorectal Cancer Metastatic 3Carcinoma, Renal Cell 3Advanced Colorectal Cancer 3Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Neoplasms 2Mesothelioma, Malignant 2Melanoma 2Lung Neoplasms 2Glioblastoma 2Gastrointestinal Neoplasms 2Gallbladder Neoplasms 2Fatigue 2Esophageal Squamous Cell Carcinoma 2Colorectal Cancer Liver Metastases 2Carcinoma, Transitional Cell 2Carcinoma, Non-Small-Cell Lung 2

Interventions

regorafenib 1Photochemotherapy 1Cholangiopancreatography, Endoscopic Retrograde 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Bile Duct Diseases × regorafenib × Gastrointestinal × Clear all
NCT02115542 2021-10-12

Single Agent Regorafenib in Refractory Advanced Biliary Cancers

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
39 enrolled 11 charts
Gastrointestinal

Bile Duct Diseases, Bile Duct Neoplasms, Carcinoma, Gallbladder Diseases, Gallbladder Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡